Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:51 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 33,137 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 3 Interventional Results available

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

NCT04938830
View directory record Official record
Conditions
RSV Infection
Interventions
Clesrovimab, Palivizumab, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 1 Year
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Long Beach, California • Orange, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 3, 2026, 7:51 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women

NCT05813067
View directory record Official record
Conditions
Vasomotor Symptoms, Postmenopausal Disorders
Interventions
JDS-HF 3.0, Placebo
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Lake Worth, Florida • Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Nov 3, 2026, 7:51 PM EST
Terminated Phase 2 Interventional Results available

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

NCT02388165
View directory record Official record
Conditions
Staphylococcal Vaccine
Interventions
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
234
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 3 Interventional Results available

A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes

NCT03309007
View directory record Official record
Conditions
PreDiabetes, Aging
Interventions
Metformin, Placebo Oral Tablet
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
30 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Nov 3, 2026, 7:51 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Macular Pigment and Visual Performance in Glaucoma Patients

NCT03959592
View directory record Official record
Conditions
Glaucoma
Interventions
Lutein, zeaxanthin and mesozeaxanthin, Placebo
Drug · Other
Lead sponsor
Felipe Medeiros, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Nov 3, 2026, 7:51 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

A Direct-to-Consumer Study Investigating the Effect of Specific Cannabinoid Products on Motivation, Energy Level, Focus, and Appetite in Healthy Adults

NCT06213064
View directory record Official record
Conditions
Motivation
Interventions
Study Product, THC Product, Placebo
Behavioral
Lead sponsor
Phylos Bioscience, Inc.
Industry
Eligibility
21 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Nov 3, 2026, 7:51 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Cardiovascular Health of Older Adults and Resveratrol (CORE)

NCT02909699
View directory record Official record
Conditions
Aging
Interventions
Observation
Other
Lead sponsor
University of Florida
Other
Eligibility
65 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 3 Interventional Results available

8-Week Atopic Dermatitis (AD) Treatment Study

NCT03386032
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Investigational OTC Cream, 0.05% Desonide, Placebo Cream
Drug · Other
Lead sponsor
Procter and Gamble
Industry
Eligibility
12 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Raleigh, North Carolina • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Nov 3, 2026, 7:51 PM EST
Terminated Not applicable Interventional

Attention Bias Modification Treatment for Anxious Youth

NCT01979263
View directory record Official record
Conditions
Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Phobia, Specific Phobia, Obsessive-Compulsive Disorder
Interventions
Attention Bias Modification Computer Task, Placebo Computer Task
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
7 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

NCT03293498
View directory record Official record
Conditions
Influenza
Interventions
NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Nov 3, 2026, 7:51 PM EST
Active, not recruiting Phase 3 Interventional

S0820, Adenoma and Second Primary Prevention Trial

NCT01349881
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2032
U.S. locations
989
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 2 Interventional

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

NCT06529419
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Placebo, Inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
45
States / cities
Mesa, Arizona • Huntington Beach, California • La Mesa, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

NCT00507130
View directory record Official record
Conditions
Asthma
Interventions
MEDI528 0.3 mg/kg, MEDI528 1 mg/kg, MEDI528 3 mg/kg, PLACEBO
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Nov 3, 2026, 7:51 PM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

NCT00849667
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Nov 3, 2026, 7:51 PM EST
Not listed Phase 4 Interventional

Dronabinol for Post-operative Pain After Lumbar Fusion

NCT04346407
View directory record Official record
Conditions
Post-operative Pain
Interventions
Dronabinol 2.5mg Cap, Placebo
Drug
Lead sponsor
Jeffrey L Gum MD
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Nov 3, 2026, 7:51 PM EST
Terminated Phase 2 Interventional Results available

Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT03720392
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation (HCT)
Interventions
FMT, Placebo
Drug
Lead sponsor
Zachariah Michael DeFilipp
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 2 Interventional Results available

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

NCT01342211
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
Placebo, Statin, PF-04950615 (RN316), Satin
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
38
States / cities
Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 3 Interventional Results available

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 2 Interventional Results available

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

NCT05407064
View directory record Official record
Conditions
Anxiety Generalized
Interventions
MM120, Placebo
Drug · Other
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Little Rock, Arkansas • Irvine, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 3 Interventional Results available

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

NCT02675998
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Huntsville, Alabama • Riverside, California • Denver, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Nov 3, 2026, 7:51 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Semi-Recumbent Vibration Therapy in Older Adults

NCT02533063
View directory record Official record
Conditions
Sarcopenia, Aging
Interventions
VibeTech One
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
70 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 1 Interventional

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

NCT03926793
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
GB002, Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Nov 3, 2026, 7:51 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

NCT04596293
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S or Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Fountain Valley, California • Lancaster, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Nov 3, 2026, 7:51 PM EST
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Nov 3, 2026, 7:51 PM EST